A team of researchers from the University of Oxford’s Zoology Department, led by Professor Sunetra Gupta, produced a model that suggests as little as 20 percent of the population may need to be resistant to the virus to prevent a resurgence of an epidemic.
The study, which was published on July 16, is yet to be peer-reviewed.
“It is widely believed that the herd immunity threshold required to prevent a resurgence of SARS-CoV-2 is in excess of 50 percent for any epidemiological setting,” the paper says.
The researchers suggest that many people may have already built up some degree of resistance to the virus from exposure to seasonal coronaviruses, such as the common cold.
Herd immunity is achieved when enough people in a population have immunity to an infection to be able to effectively stop that disease from spreading. It lowers the chances of the virus being transmitted from person to person and reaching those who haven’t been infected yet.
People can become immune to certain viruses after surviving infection or being vaccinated. Typically, at least 70 percent of a population must be immune to achieve herd immunity. But how long immunity lasts varies depending on the virus.
“Here, we demonstrate that HIT may be greatly reduced if a fraction of the population is unable to transmit the virus due to innate resistance or cross-protection from exposure to seasonal coronaviruses,” wrote study authors Jose Lourenco, Francesco Pinotti, Craig Thompson, and Gupta.
“These results help to explain the large degree of regional variation observed in seroprevalence and cumulative deaths, and suggest that sufficient herd immunity may already be in place to substantially mitigate a potential second wave,” they added.
The researchers said that when people who are resistant to a virus mix with non-resistant people, the HIT drops significantly.
“Given the mounting evidence that exposure to seasonal coronaviruses offers protection against clinical symptoms, it would be reasonable to assume that exposure to SARS-CoV-2 itself would confer a significant degree of clinical immunity,” the researchers suggest.
“Thus, a second peak may result in far fewer deaths, particularly among those with comorbidities in the younger age classes.”